Danguole Altman is the President and CEO of Cx Precision Medicine, which develops AI-driven tests to improve the diagnosis and treatment of neurodegenerative diseases. She is also a Partner at Newport LLC. With experience founding, leading, and growing innovative life science and healthcare services companies, Danguole founded Vapogenix, a non-opioid pain therapeutics firm, and co-founded FemPartners, a women’s healthcare services company.

Early diagnosis of degenerative diseases like Alzheimer’s is critical for effective treatment. Yet, primary care physicians often lack clear, efficient tools to assess cognitive decline, leaving patients and families in limbo. How can innovation bridge the gap between clinical complexity and accessible early intervention?

Healthcare innovation entrepreneur Danguole Altman has dedicated her career to providing access to cutting-edge diagnostic tools. She emphasizes the importance of aligning business leadership with medical expertise to identify gaps in care. These partnerships and collaborations allow businesses to build diagnostic tools tailored for primary care, prioritize early payer engagement, and mitigate regulatory risks.

In this episode of Growth + Exit, Susan Kearney welcomes Danguole Altman, President and CEO of Cx Precision Medicine, to discuss innovating preventative care diagnostics. Danguole talks about designing solutions that fit real-world constraints, remaining resilient amid market disruptions, and building mission-aligned teams.